Hereditary Cancer Panel denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step-Therapy to Hereditary Cancer Panel Testing

Step-therapy — sometimes called "fail-first" — is most commonly associated with medications, but UnitedHealthcare may apply a similar sequential-testing requirement to hereditary cancer panels. This typically means UHC requires that a narrower, single-gene test (such as a test for a single high-penetrance gene) be attempted and found non-informative before authorizing a broader multi-gene panel. The denial signals that UHC believes the patient should have started with a more limited test, and that the panel was ordered prematurely.

## Why This Denial Is Appealable

Step-therapy in genetic testing is clinically contested. Major professional organizations in genetics and oncology have published positions supporting multi-gene panel testing as a first-line approach in appropriate clinical contexts, because sequential single-gene testing is slower, often more expensive in aggregate, and can miss clinically significant variants in genes not covered by the initial test. If the ordering clinician or genetic counselor can document that a sequential approach would be clinically inferior or harmful for this patient, the step-therapy requirement is directly challengeable. Refer to the applicable NCCN, ACMG, or relevant professional society guidance for the relevant position — but do not cite specific numeric thresholds or statistics in the appeal letter.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plans) or applicable state law within the timeframe on the denial notice. Request that the reviewer specifically address the clinical literature on sequential vs. panel-first testing.
• External review: After exhausting internal remedies, ACA §2719 entitles you to independent review by an IRO. The standard window is approximately four months from the final internal denial. Expedited review is available if clinical circumstances are urgent (e.g., surgical decision pending).

## Concrete Appeal Steps and Timeline

1. Obtain UHC's step-therapy policy for hereditary cancer testing — specifically which prior test(s) are required and what result UHC considers sufficient to proceed. 2. Have the ordering clinician or genetic counselor document why single-gene sequential testing is clinically inferior for this patient's specific indication. 3. If any prior single-gene testing has already been performed, include those results and explain why they are insufficient to address the full clinical picture. 4. Submit a Level 1 internal appeal with a clinical rationale letter and any supporting professional society position statements. 5. If denied internally, escalate to external IRO review.

## Documentation to Gather

• Step requirement details: The specific UHC policy requiring sequential testing — gene(s) required first, and the required result type.
• Clinical inferiority argument: A written statement from the ordering clinician or genetic counselor explaining why sequential testing is not appropriate for this patient (e.g., family history pattern implicating multiple genes simultaneously, clinical urgency, cost-effectiveness of panel-first approach).
• Prior testing record (if any): Results of any prior single-gene tests already completed, with interpretation.
• Professional society position: A reference to the relevant guideline organization's recommendation on panel vs. sequential testing for this indication — cited by organization name, not by specific numbers.
• Clinical management impact: How a multi-gene panel result — compared to a sequential approach — will materially change the patient's care plan and timeline.

## Criteria-Mapping Structure

Copy UHC's step-therapy criteria for this test category. For each step, document either (a) that the step has already been completed with the required result, or (b) the specific clinical reason why the step is not appropriate for this patient. The strongest appeals combine a completed-step argument with a clinical-necessity argument as an alternative ground, so the reviewer cannot deny on the step alone.